Skip to content

Study · Randomized controlled trial · n = 13 · 2020

7 results

Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.

Del Olmo-García MI, Hervás Marín D, Caudet Esteban J, Ballesteros Martin-Portugués A, Cerveró Rubio A, Arnau Vives MA, Catalá Gregori A, Penalba Martínez M, Merino-Torres JF

The Journal of international medical research1 Jun 2020Cited by 3 (Europe PMC)

PMID32567433 (opens in a new tab)PMCIDPMC7309403 (opens in a new tab)DOI10.1177/0300060520926063 (opens in a new tab)PepBankPUB-32567433
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and acute coronary syndrome, mean glucose during hospitalization was 164.75 mg/dL with liraglutide and 166.69 mg/dL with glargine.

    In plain wordsIn patients with type 2 diabetes and acute coronary syndrome, average hospital glucose was similar with liraglutide and with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedMean glucose during hospitalization
    Study

    n = 13

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Mean glucose
    164.75 mg/dL
    liraglutide
    Mean glucose
    166.69 mg/dL
    glargine

    Source sentences

    Summary
    During hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in group 1 and 166.69 mg/dL (38.22) in group 2.
    1 context sentence
    Summary · context
    A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and acute coronary syndrome, glycemic variability measured by CV was lower with liraglutide than with glargine during hospitalization.

    In plain wordsIn patients with type 2 diabetes and acute coronary syndrome, blood glucose swung less with liraglutide than with insulin glargine during the hospital stay.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic variability by coefficient of variation during hospitalization
    Study

    n = 13

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Glycemic variability CV
    20.98
    liraglutide
    Glycemic variability CV
    25.48
    glargine

    Source sentences

    Summary
    GV determined by CV and SD was 20.98 (7.68) vs. 25.48 (7.19) and 34.37 (13.05) vs. 43.56 (19.53) in groups 1 and 2, respectively.
    1 context sentence
    Summary · context
    A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and acute coronary syndrome, glycemic variability measured by SD was lower with liraglutide than with glargine during hospitalization.

    In plain wordsIn patients with type 2 diabetes and acute coronary syndrome, blood glucose swung less with liraglutide than with insulin glargine during the hospital stay.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic variability by standard deviation during hospitalization
    Study

    n = 13

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Glycemic variability SD
    34.37
    liraglutide
    Glycemic variability SD
    43.56
    glargine

    Source sentences

    Summary
    GV determined by CV and SD was 20.98 (7.68) vs. 25.48 (7.19) and 34.37 (13.05) vs. 43.56 (19.53) in groups 1 and 2, respectively.
    1 context sentence
    Summary · context
    A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and acute coronary syndrome, prandial insulin requirements during hospitalization were lower with liraglutide than with glargine.

    In plain wordsIn patients with type 2 diabetes and acute coronary syndrome, liraglutide patients needed less mealtime insulin in hospital than glargine patients.

    Peptide
    Liraglutide
    Outcome
    DecreasePrandial insulin requirements during hospitalization
    Study

    n = 13

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Group 1 prandial insulin requirements during hospitalization were lower compared with group 2.
    1 context sentence
    Summary · context
    A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and acute coronary syndrome, follow-up A1c was 6.9% with liraglutide (change -1.51%) and 6.5% with glargine (change -1.27).

    In plain wordsIn patients with type 2 diabetes and acute coronary syndrome, A1c fell in both the liraglutide group and the glargine group.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedFollow-up HbA1c
    Study

    n = 13

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    HbA1c at follow-up
    6.9%
    liraglutide
    HbA1c at follow-up
    6.5%
    glargine
    HbA1c change
    −1.51%
    liraglutide
    HbA1c change
    −1.27
    glargine

    Source sentences

    Summary
    Follow-up A1c in group 1 was 6.9% (-1.51%) and 6.5% in group 2 (-1.27).
    1 context sentence
    Summary · context
    A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and acute coronary syndrome, glycemic variability after discharge was lower with liraglutide than with glargine.

    In plain wordsIn patients with type 2 diabetes and acute coronary syndrome, blood glucose swung less after discharge with liraglutide than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic variability after discharge
    Study

    n = 13

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    GV after discharge and hypoglycemia were lower in group 1 compared with group 2
    1 context sentence
    Summary · context
    A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV.
  7. 07HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes and acute coronary syndrome, hypoglycemia was lower with liraglutide than with glargine.

    In plain wordsIn patients with type 2 diabetes and acute coronary syndrome, low blood sugar happened less with liraglutide than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycemia
    Study

    n = 13

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    GV after discharge and hypoglycemia were lower in group 1 compared with group 2.
    1 context sentence
    Summary · context
    A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.